About Bukwang Pharmaceutical
Bukwang Pharmaceutical is a publicly listed company based in South Korea. Pharmaceutical products are developed, manufactured, and marketed in South Korea. It operates on a HealthTech and Direct-to-Consumer (D2C) model. Bukwang Pharmaceutical has raised $5.2 million across 1 funding round from investors including TVM Capital Life Science. Bukwang Pharmaceutical has completed 1 acquisition, including Korea Union Pharmaceuticals. Its website bukwang.co.kr draws about 143 thousand monthly visits. Bukwang Pharmaceutical offers products and services including Lurasidone, JM-010, SOL-804, and Legadex. Its focus areas include Pharmaceuticals and Prescription Drugs. Its legal entity is Bukwang Pharm Co., Ltd.
Company details
Bukwang Pharmaceutical is involved in the research, development, and production of pharmaceutical products, including prescription medicines, over-the-counter drugs, and health supplements. The company operates in the healthcare sector, focusing on innovative drug development for conditions such as schizophrenia, Parkinsons disease, and prostate cancer. Solutions are provided through a robust pipeline and open innovation strategies, aiming for global expansion as a leading pharmaceutical entity. Emphasis is placed on sustainability and ethical governance to ensure a healthier future.
- Headquarters South Korea
- Stage Public
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website bukwang.co.kr
- Legal Name Bukwang Pharmaceutical Co., Ltd.
- Annual Revenue$138.98 M (USD)25.38as on Dec 31, 2025
- Net Profit$8.7 M (USD)as on Dec 31, 2025
- EBITDA$13.61 M (USD)243.35as on Dec 31, 2025
- Total Equity Funding$5.2M (USD)
in 1 rounds
- Latest Funding Round$5.2M (USD), Series A
Mar 2017
- Investors
- Investments & Acquisitions
Products & Services of Bukwang Pharmaceutical
Bukwang Pharmaceutical offers a comprehensive portfolio of products and services, including Lurasidone, JM-010, SOL-804, and Legadex.
Used for treating schizophrenia and bipolar depression effectively.
Developed for treating dyskinesia in Parkinson’s disease patients.
Designed for metastatic castration-resistant prostate cancer treatment.
Formulated as a liver disease treatment compound drug.
Funding Insights of Bukwang Pharmaceutical
Bukwang Pharmaceutical has successfully raised a total of $5.2M through 1 strategic funding round. The most recent funding activity was a Series A round of $5.2 million completed in March 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $5.2M
- Total Rounds 1
- Last Round Series A — $5.2M
- First Round $5.2M
(Mar 2017)
- Investors Count 1
All 1 funding rounds of Bukwang Pharmaceutical with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Mar 2017 | $5.2M | Series A | – | – |
1 investors in total: 1 institutional.
Investors in Bukwang Pharmaceutical
Bukwang Pharmaceutical has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include TVM Capital Life Science.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Life Science focused early stage VC firm investing in Europe, Canada, the USA and Asia | tvm-lifescience.com | Munich, Germany |
Investor details for Bukwang Pharmaceutical
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Bukwang Pharmaceutical
2 people are tracked at Bukwang Pharmaceutical (2 in leadership).
| Name | Role | Group |
|---|---|---|
Hee-Won Yoo | CEO | Leadership |
Sun Ho Kim | Senior Managing Director | Leadership |
Complete people profiles for Bukwang Pharmaceutical
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Bukwang Pharmaceutical
Bukwang Pharmaceutical is a publicly listed company on the KRX with ticker symbol 003000 in South Korea, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date05 Aug 1988
- Listed onKRX: 003000
- Listed entityBukwang Pharmaceutical Co., Ltd.
- Exchange sectorHealth technology
- ISINKR7003000007
- Share price3,835.00 KRW (-1.92% on the day) · 2026-10-14
- Market capitalisation385,778,870,850.00 KRW
- Price to earnings43.1
- EPS (diluted, trailing year)88.97 KRW
- Dividend yield3.2%
- Volume (last session)194,001
Financials of Bukwang Pharmaceutical
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 200.71B KRW | 12.56B KRW | 19.65B KRW |
| 2024 | 160.09B KRW | -2.64B KRW | 5.72B KRW |
| 2023 | 125.93B KRW | -31.33B KRW | -33.20B KRW |
| 2022 | 190.91B KRW | -2.47B KRW | 4.89B KRW |
| 2021 | 182.49B KRW | -916.6M KRW | 10.46B KRW |
Detailed financial statements for Bukwang Pharmaceutical
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Bukwang Pharmaceutical
Bukwang Pharmaceutical has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Korea Union Pharmaceuticals.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Utility industry construction, inspection, and maintenance services are provided. | ukp.co.kr | Seongnam-si, South Korea | 1956 | Dec 2025 | •••• |
Complete acquisition details for Bukwang Pharmaceutical
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Bukwang Pharmaceutical
3 dated milestones of Bukwang Pharmaceutical across 37 years, from founding to its latest funding, stage changes and deals.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $5.2M.
- Acquisition Acquires Korea Union Pharmaceuticals.
Web traffic of Bukwang Pharmaceutical
The website of Bukwang Pharmaceutical (bukwang.co.kr) receives about 142.7K visits a month and ranks #395,152 among all websites worldwide, #344 in Biotechnology and Pharmaceuticals.
- Monthly visits142.7K
▲ 109.3% vs previous month
- Unique visitors10.9K
per month
- Global rank#395,152
among all websites
- Category rank#344
Health · Biotechnology and Pharmaceuticals
- Bounce rate21%
- Pages per visit7.4
- Average visit8 min 38 sec
- DevicesDesktop 51% · Mobile 49%
Websites whose visitors overlap most with Bukwang Pharmaceutical. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| boryung.co.kr | 100% | 106.1K | #241,973 | View details | |
| donga.co.kr | 91% | 17.1K | #1,381,945 | View details | |
| daewonpharm.com | 79% | 95.4K | View details | ||
| sspharm.co.kr | 74% | 5.9K | #1,210,844 | View details | |
| yuhan.co.kr | 73% | #155,074 | View details | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Bukwang Pharmaceutical
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Bukwang Pharmaceutical
Complete news archive for Bukwang Pharmaceutical
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Bukwang Pharmaceutical
Bukwang Pharmaceutical is headquartered in South Korea.
Bukwang Pharmaceutical is a funded company, having raised a total of $5.2M across 1 funding round to date. The company's 1st funding round was a Series A of $5.2M, raised on Mar 2017.
Annual revenue of Bukwang Pharmaceutical is $138.98M as on Dec 31, 2025.
Bukwang Pharmaceutical is involved in the research, development, and production of pharmaceutical products, including prescription medicines, over-the-counter drugs, and health supplements. The company operates in the healthcare sector, focusing on innovative drug development for conditions such as schizophrenia, Parkinsons disease, and prostate cancer. Solutions are provided through a robust pipeline and open innovation strategies, aiming for global expansion as a leading pharmaceutical entity. Emphasis is placed on sustainability and ethical governance to ensure a healthier future.
Bukwang Pharmaceutical offers Lurasidone, JM-010, SOL-804, and Legadex.
Yes, Bukwang Pharmaceutical is publicly traded on KRX under the ticker symbol 003000.
Bukwang Pharmaceutical has made 1 acquisition, including Korea Union Pharmaceuticals.
Bukwang Pharmaceutical has 1 investor. Key investors include TVM Capital Life Science.
Bukwang Pharmaceutical operates through Bukwang Pharm Co., Ltd..
The website of Bukwang Pharmaceutical receives about 143 thousand visits a month and ranks #395,152 among all websites worldwide.